Clinical Trials Today reports that WuXi Pharma Tech, which is a Chinese contract research organization, is discontiunuing its U.S. biologics manufacturing operations as of December 31st, and as a result of this the company will be cutting nearly 100 manufacturing positions across its Philadelphia facility.
The restructuring of the CRO will cost the company between $2.5 million and $3.5 million within the next couple of months. WuXi CFO Benson Tsang recently mentioned:
“Given the depressed demand and the high cost structure of our biologics manufacturing services, we will focus on expanding our biologics testing, cell banking and cell therapy services in our Philadelphia site instead.”
Wednesday, December 3, 2008
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment